US30052C1071
US30052C1071
Evolus, Inc. Common Stock
Loading chart...
Company Profile
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Latest News

Zacks • 10/08/2026
UTMD Trades at a Premium to the Industry: How to Play the Stock?
Stocktwits • 10/02/2026
FDA Flags Evolus’ Jeuveau Instagram Promotion As Misleading, Seeks Corrective Action

Insider Monkey • 09/09/2026
Evolus (EOLS) Notches A Profit Milestone While Betting Big On The Future

GlobeNewswire • 08/31/2026
Telix Appoints David Gill as Chair
Related stocks
Key Metrics & Overview
Detailed metrics & financial data of the company
Company Profile
5
MetricsCountry
Region
Sector
Website
🛡️ Risk & Structural Analysis
Multi-Factor Risk Model & Market Data
7/7 Very High
5Y Volatility
62.1% p.a.
Max Drawdown (5Y)
-77.5%
Sharpe Ratio (5Y)
0.00
Beta Factor
1.34
Size Class
Small Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (62.1% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -92.4% in the extended horizon.